Moore Capital Management, LP Viking Therapeutics, Inc. Transaction History

Moore Capital Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$10.92 - $16.0 $546,000 - $800,000	50,000 New	50,000 $553,000
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $272,000 - $940,000	100,000 New	100,000 $940,000
Q3 2018 Nov 14, 2018	SELL	$9.7 - $19.65 $969,999 - $1.96 Million	-100,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $388,000 - $1.27 Million	100,000 New	100,000 $949,000

442

63.3M

6.23M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.23B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.